BC-CfE submitted Health Canada “Special Access Program” application to provide two investigational HIV drugs to six patients resistant to all other therapies. Health Canada denies the BC-CfE access and the BC-CfE publicly campaigns for access. Health Canada reverses its decision and the BC-CfE is first to prescribe the combination of TMC114 (darunavir) and TMC125 (etravirine) together to the remaining five patients.
BC-CfE’s research lab demonstrated the effect of impact of human and virus genetics in the response to HAART treatments.
BC-CfE launched large cohort of women in sex work to examine their sexual health and HIV needs and barriers to care.
Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.
The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)
